Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Voyager Therapeutics (VYGR) EBITDA (2016 - 2025)

Historic EBITDA for Voyager Therapeutics (VYGR) over the last 11 years, with Q3 2025 value amounting to -$27.7 million.

  • Voyager Therapeutics' EBITDA fell 22336.65% to -$27.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$126.7 million, marking a year-over-year decrease of 58569.46%. This contributed to the annual value of -$65.4 million for FY2024, which is 14932.87% down from last year.
  • Latest data reveals that Voyager Therapeutics reported EBITDA of -$27.7 million as of Q3 2025, which was down 22336.65% from -$33.4 million recorded in Q2 2025.
  • In the past 5 years, Voyager Therapeutics' EBITDA ranged from a high of $124.1 million in Q1 2023 and a low of -$34.9 million during Q4 2024
  • In the last 5 years, Voyager Therapeutics' EBITDA had a median value of -$21.6 million in 2021 and averaged -$7.5 million.
  • As far as peak fluctuations go, Voyager Therapeutics' EBITDA plummeted by 51249.34% in 2022, and later skyrocketed by 67994.3% in 2023.
  • Quarter analysis of 5 years shows Voyager Therapeutics' EBITDA stood at $5.7 million in 2021, then crashed by 512.49% to -$23.5 million in 2022, then surged by 340.75% to $56.6 million in 2023, then crashed by 161.6% to -$34.9 million in 2024, then rose by 20.64% to -$27.7 million in 2025.
  • Its EBITDA was -$27.7 million in Q3 2025, compared to -$33.4 million in Q2 2025 and -$30.8 million in Q1 2025.